MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MaxCyte, a commercial cell-engineering company, has granted stock options for 204,500 shares to eight new employees as part of its 2021 Inducement Plan. This move, effective from February 10, 2022, aligns with Nasdaq rules and aims to incentivize talent acquisition. Each option has a ten-year term with an exercise price of $6.54, matching the stock's closing price on the grant date. Vesting occurs over four years, with 25% available after the first year. This initiative underscores MaxCyte's commitment to enhancing its workforce to drive next-generation cell-based medicine advancements.
- Stock options granted to eight new employees, enhancing talent acquisition.
- Incentives align with Nasdaq rules, boosting investor confidence.
- None.
GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that, on February 10, 2022, the Compensation Committee of MaxCyte’s Board of Directors granted stock options to purchase an aggregate of 204,500 shares of MaxCyte’s common stock to eight (8) newly hired employees. The stock options were granted as material inducements to employment with MaxCyte in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the MaxCyte, Inc. 2021 Inducement Plan (the “2021 Inducement Plan”).
The stock options have a ten-year term and an exercise price of
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.
MaxCyte Contacts:
| US IR Adviser Gilmartin Group David Deuchler, CFA | +1 415-937-5400 ir@maxcyte.com |
| Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden | +44 (0)20 7886 2500 |
| UK IR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh | +44 (0)203 709 5700 maxcyte@consilium-comms.com |
FAQ
What stock options did MaxCyte announce on February 10, 2022?
What is the exercise price for the stock options granted by MaxCyte?
What is the vesting period for the stock options granted by MaxCyte?
How does the stock option grant impact MaxCyte's workforce?
What plan governs the stock options granted by MaxCyte?
